QQ客服 官方微博 反馈留言

	Placenta chondroitin sulfate A binding peptide modified dendrigraft poly-L-lysinesloaded with endophytic bacteria prodigiosin for targeted choriocarcinoma therapy
	Dan Li; Guogang Cheng; Kai Zhao; Jie Chen; Baobei Wang; Xiujun Fan
	2016
会议名称	The 4th SKLRB Symposium on Reproductive Biology
会议地点	中国北京
英文摘要	Choriocarcinoma is a malignant tumor arising from trophoblastic cells and characterized by the secretion of human chorionic gonadotropin (hCG). The lung and the vagina are the common target organs of choriocarcinoma metastasis. Achieving effective targeted therapy for choriocarcinoma depends on drug delivery systems. We developed a novel drug vectors composed of dendrigraft poly-L-lysine (DGL) modified by a placenta chondroitin sulfate A (pl-CSA) binding peptide. This drug delivery system was able to load endophytic bacteria prodigiosin (PG) isolated from serratia marcescens subsp. lawsoniana and further target choriocarcinoma. Briefly, DGLs, a novel nonviral drug and gene vectors, are conjugated to a pl-CSA binding peptide, which is specifically binding to the CSA expressed only in the trophoblastic origin cells. This process yields peptide-modified nanoparticles (DGL-CSA-NPs), and PG-DGL-CSA-NPs after PG encapsulated by emulsion-solvent evaporation method method. Meantime, PG-DGL-NPs was made by loading PG into DGL, and PG-DGL-SCR-NPs was made by conjugating a random sequence peptide to DGL and loaded with PG. The properties of the resulting nanoparticles were determined by transmission electron microscopy, Zeta potential analysis. The results showed that PG-DGL-NPs had regular spherical morphologies and high stability. An in vitro release assay indicated that the release of PG from PG-DGL-PEG-CSA-NPs occurred slowly at pH 7.4. Cellular uptake and in vivo imaging results indicate that PG-DGL-CSA-NPs have a better choriocarcinoma tumor targeted effect compared with PG-DGL-SCR-NPs and DGL-NPs control group after intravenous injection. Meantime, the results also showed that DGL had low toxicity and a high safety level. Besides, in vivo JEG-3 tumor model showed that animals in the PG-DGL-CSA-NPs group also exhibited a prolonged median survival time compare to other groups. In conclusion, DGL-NPs are a novel drug delivery carrier and PG-DGL-CSA-NPs exhibit potential as an efficient, noninvasive, and safe choriocarcinoma targeted drug delivery.
收录类别	其他
语种	英语
内容类型	会议论文
源URL	[http://ir.siat.ac.cn:8080/handle/172644/10829]
专题	深圳先进技术研究院_医药所
作者单位	2016
推荐引用方式 GB/T 7714	Dan Li,Guogang Cheng,Kai Zhao,et al. Placenta chondroitin sulfate A binding peptide modified dendrigraft poly-L-lysinesloaded with endophytic bacteria prodigiosin for targeted choriocarcinoma therapy[C]. 见:The 4th SKLRB Symposium on Reproductive Biology. 中国北京.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。